Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644 · see citing works

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works

Molecular anatomy of a trafficking organelle

Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373 · see citing works

Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

Feigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275 · see citing works

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · see citing works

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

Biomarkers for Alzheimer's disease: current status and prospects for the future

Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · see citing works

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease

Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720 · see citing works

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633 · see citing works

Imaging synaptic density in the living human brain

Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · see citing works

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works

Differential expression of synaptic vesicle protein 2 (SV2) isoforms

Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440 · see citing works

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging

Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431 · see citing works

Synaptic Impairment in Alzheimer’s Disease: A Dysregulated Symphony

Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.002 · Cited by 430 · see citing works

Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1× · see citing works

SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release

Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 366 · see citing works

[18F]FDG PET signal is driven by astroglial glutamate transport

Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H.-I., Gauthier, S., Pellerin, L., Hamel, E., & Rosa-Neto, P. (2017) · Nature Neuroscience · doi:10.1038/nn.4492 · Cited by 343 · see citing works

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 339 · see citing works

Synthesis and Preclinical Evaluation of ¹¹ C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain

Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296 · see citing works

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · see citing works

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease

Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279 · see citing works

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

Magdalinou, N. K., Paterson, R. W., Schott, J. M., Fox, N. C., Mummery, C. J., Blennow, K., Bhatia, K. P., Morris, H. R., Giunti, P., Warner, T. T., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309562 · Cited by 250 · see citing works

Increased CSF neurogranin concentration is specific to Alzheimer disease

Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · see citing works

Kinetic evaluation and test–retest reproducibility of [ ¹¹ C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans

Finnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218 · see citing works

Establishing the Proteome of Normal Human Cerebrospinal Fluid

Schutzer, S. E., Liu, T., Natelson, B. H., Angel, T. E., Schepmoes, A., Purvine, S. O., Hixson, K. K., Lipton, M. S. W., Camp, D., Coyle, P. K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010980 · Cited by 217 · see citing works

SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family

Janz, R., & Südhof, T. C. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00370-x · Cited by 214 · see citing works

MicroRNA regulation of homeostatic synaptic plasticity

Cohen, J. E., Lee, P. R., Chen, S., Li, W., & Fields, R. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017576108 · Cited by 214 · see citing works

Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele

Blennow, K., Bogdanović, N., Alafuzoff, I. I., Ekman, R., & Davidsson, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01273157 · Cited by 207 · see citing works

Review: Parkinson's disease: from synaptic loss to connectome dysfunction

Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., & Spano, P. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12297 · Cited by 203 · see citing works

Protein Quantification at the Single Vesicle Level Reveals That a Subset of Synaptic Vesicle Proteins Are Trafficked with High Precision

Mutch, S. A., Kensel-Hammes, P., Gadd, J. C., Fujimoto, B. S., Allen, R. W., Schiro, P. G., Lorenz, R. M., Kuyper, C. L., Kuo, J. S., Bajjalieh, S. M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3805-10.2011 · Cited by 185 · see citing works

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0208-8 · Cited by 184 · see citing works

Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., Carlo, C. D., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 170 · see citing works

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology

Portelius, E., Olsson, B., Höglund, K., Cullen, N. C., Kvartsberg, H., Andréasson, U., Zetterberg, H., Sandelius, Å., Shaw, L. M. J., Lee, V. M. ‐., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1851-x · Cited by 167 · see citing works

Cotrafficking of SV2 and synaptotagmin at the synapse

Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · see citing works

Perforant path synaptic loss correlates with cognitive impairment and Alzheimer’s disease in the oldest-old

Robinson, J. L., Molina-Porcel, L., Corrada, M. M., Raible, K., Lee, E. B., Lee, V. M.-Y., Kawas, C. H., & Trojanowski, J. Q. (2014) · Brain · doi:10.1093/brain/awu190 · Cited by 157 · see citing works

Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP

Wang, Z., Jackson, R. J., Hong, W., Taylor, W. M., Corbett, G. T., Moreno, A. J., Liu, W., Li, S., Frosch, M. P., Slutsky, I., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2009-17.2017 · Cited by 154 · see citing works

Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.

Herholz, K., Schopphoff, H., Schmidt, M. V., Mielke, R., Eschner, W., Scheidhauer, K., Schicha, H., Heiss, W., & Ebmeier, K. P. (2002) · PubMed · Cited by 151 · see citing works

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein

Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148 · see citing works

Synaptotoxic Amyloid-β Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?

Klein, W. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129039 · Cited by 141 · see citing works

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137 · see citing works

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

Hellwig, K., Kvartsberg, H., Portelius, E., Andréasson, U., Oberstein, T. J., Lewczuk, P., Blennow, K., Kornhuber, J., Maler, J. M., Zetterberg, H., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0161-y · Cited by 136 · see citing works

Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies

Hsiao, I.-T., Huang, C.-C., Hsieh, C.-J., Hsu, W.-C., Wey, S., Yen, T., Kung, M.-P., & Lin, K.-J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2051-2 · Cited by 135 · see citing works

Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies

Oeckl, P., Metzger, F., Nagl, M., Arnim, C. A. F. V., Halbgebauer, S., Steinacker, P., Ludolph, A. C., & Otto, M. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.059915 · Cited by 135 · see citing works

Synaptic vesicle protein 2A: basic facts and role in synaptic function

Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124 · see citing works

Small-molecule PET Tracers for Imaging Proteinopathies

Mathis, C. A., Lopresti, B. J., Ikonomović, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 122 · see citing works

Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue

Koole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., Mercier, J., Sciberras, D., Maguire, P., & Van Laere, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4119-8 · Cited by 118 · see citing works

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

Simonsen, A., Mcguire, J., Podust, V., Davies, H., Minthon, L., Skoog, I., Andreasen, N., Wallin, A., Waldemar, G., & Blennow, K. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.01.011 · Cited by 108 · see citing works

Puzzling Out Synaptic Vesicle 2 Family Members Functions

Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107 · see citing works

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease

Initiative, T. A. D. N., Zhang, H., Therriault, J., Kang, M. S., Ng, K. P., Pascoal, T. A., Rosa‐Neto, P., & Gauthier, S. G. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0407-6 · Cited by 93 · see citing works

A review of β-amyloid neuroimaging in Alzheimer's disease

Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93 · see citing works

Linking Amyloid-β and Tau: Amyloid-β Induced Synaptic Dysfunction via Local Wreckage of the Neuronal Cytoskeleton

Zempel, H., & Mandelkow, E. (2011) · Neurodegenerative Diseases · doi:10.1159/000332816 · Cited by 90 · see citing works

Effects of Levetiracetam on Tardive Dyskinesia

Woods, S. W., Saksa, J. R., Baker, C. B., Cohen, S. J., & Tek, C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0405 · Cited by 87 · see citing works

Radioligand development for molecular imaging of the central nervous system with positron emission tomography

Honer, M., Gobbi, L. B., Martarello, L., & Comley, R. A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.012 · Cited by 87 · see citing works

Non-Fibrillar Oligomeric Amyloid-β within Synapses

Pickett, E. K., Koffie, R. M., Wegmann, S., Henstridge, C. M., Herrmann, A. G., Colom‐Cadena, M., Lleó, A., Kay, K. R., Vaught, M., Soberman, R. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160007 · Cited by 87 · see citing works

Neurophysiology of synaptic functioning in multiple sclerosis

Bassi, M. S., Mori, F., Buttari, F., Marfia, G. A., Sancesario, A., Centonze, D., & Iezzi, E. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.04.006 · Cited by 87 · see citing works

Evaluation of¹⁸F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain

Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85 · see citing works

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

Constantinescu, C. C., Tresse, C., Zheng, M., Gouasmat, A., Carroll, V. M., Mistico, L., Alagille, D., Sandiego, C. M., Papin, C., MAREK, K. L., et al. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1260-5 · Cited by 75 · see citing works

Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET

Chen, Y. J., Rosario, B. L., Mowrey, W. B., Laymon, C. M., Lu, X., López, O. L., Klunk, W. E., Lopresti, B. J., Mathis, C. A., & Price, J. C. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152405 · Cited by 74 · see citing works

Down-regulation Synaptic Vesicle Protein 2A in the Anterior Temporal Neocortex of Patients with Intractable Epilepsy

Feng, G., Xiao, F., Lü, Y., Huang, Z., Yuan, J., Xiao, Z., Xi, Z., & Wang, X. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9288-2 · Cited by 71 · see citing works

[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A

Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71 · see citing works

Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands

Mercier, J., Archen, L., Bollu, V., Carré, S., Evrard, Y., Jnoff, E., Kenda, B., Lallemand, B., Michel, P., Montel, F., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300482 · Cited by 68 · see citing works

Expression pattern of synaptic vesicle protein 2 ( SV 2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis

Crèvecœur, J., Kaminski, R. M., Rogister, B., Foerch, P., Vandenplas, C., Neveux, M., Mazzuferi, M., Kroonen, J., Poulet, C., Martin, D., et al. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12054 · Cited by 68 · see citing works

The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.

Seifert, K. D., & Wiener, J. I. (2013) · Europe PMC (PubMed Central) · Cited by 66 · see citing works

Prospects of Levetiracetam as a Neuroprotective Drug Against Status Epilepticus, Traumatic Brain Injury, and Stroke

Shetty, A. K. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00172 · Cited by 65 · see citing works

Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma

de Groot, M., Aronica, E., Heimans, J. J., & Reijneveld, J. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c110 · Cited by 64 · see citing works

Measuring brain synaptic vesicle protein 2A with positron emission tomography and [ ¹⁸ F]UCB‐H

Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61 · see citing works

Levetiracetam for managing neurologic and psychiatric disorders

Farooq, M. U., Bhatt, A., Majid, A., Gupta, R. G., Khasnis, A. A., & Kassab, M. Y. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070607 · Cited by 60 · see citing works

Comparability of [ 18 F]THK5317 and [ 11 C]PIB blood flow proxy images with [ 18 F]FDG positron emission tomography in Alzheimer’s disease

Rodriguez‐Vieitez, E., Leuzy, A., Chiotis, K., Saint‐Aubert, L., Wall, A. E., & Nordberg, A. K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16645593 · Cited by 59 · see citing works

Radiosynthesis of ¹¹C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression

Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500285t · Cited by 58 · see citing works

Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [18F]UCB-H: First-in-Human Study

Bretin, F., Bahri, M. A., Bernard, C., Warnock, G., Aerts, J. J., Mestdagh, N., Buchanan, T. J., Otoul, C., Koestler, F., Miévis, F., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0820-6 · Cited by 54 · see citing works

Expression of SV2 isoforms during rodent brain development

Crèvecœur, J., Foerch, P., Doupagne, M., Thielen, C., Vandenplas, C., Moonen, G., Deprez, M., & Rogister, B. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-87 · Cited by 51 · see citing works

Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H

Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-35 · Cited by 43 · see citing works

Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson’s disease

Tsui, A., & Ole Isacson, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6061-6 · Cited by 38 · see citing works

Reduced Uptake of 18 F-FDG and 15 O-H 2 O in Alzheimer'S Disease-Related Regions after Glucose Loading

Ishibashi, K., Kawasaki, K., Ishiwata, K., & Ishii, K. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.127 · Cited by 37 · see citing works

Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding

Shi, J., Anderson, D. B., Lynch, B. A., Castaigne, J., Foerch, P., & Lebon, F. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391341 · Cited by 33 · see citing works

Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease

Chatterjee, M., del Campo, M., Morrema, T. H. J., de Waal, M. W. J., van der Flier, W. M., Hoozemans, J. J. M., & Teunissen, C. E. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0383-x · Cited by 33 · see citing works

Pharmacokinetic Characterization of [¹⁸F]UCB-H PET Radiopharmaceutical in the Rat Brain

Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31 · see citing works

Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

Zesiewicz, T. A., Sullivan, K. L., Hauser, R. A., & Sanchez‐Ramos, J. (2006) · Movement Disorders · doi:10.1002/mds.21061 · Cited by 31 · see citing works

Fluorescence-Based Molecular Imaging of Porcine Urinary Bladder Sentinel Lymph Nodes

Lee, H. J., Barback, C. V., Hoh, C. K., Qin, Z., Kader, K., Hall, D. J., Vera, D. R., & Kane, C. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178582 · Cited by 26 · see citing works

Levetiracetam as an alternative therapy for Tourette syndrome

Granero, M. Á. M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s6371 · Cited by 21 · see citing works

Preparation of 99mTc-levetiracetam intranasal microemulsion as the first radiotracer for SPECT imaging of the Synaptic Vesicle Protein SV2A

Rashed, H. M., Shamma, R. N., & El-Sabagh, H. A. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.05.019 · Cited by 20 · see citing works

Age and sex effects on synaptic density in healthy humans as assessed with SV2A PET

Carson, R. E., Naganawa, M., Matuskey, D., Mecca, A. P., Pittman, B. P., Toyonaga, T., Lu, Y., Dias, M., Nabulsi, N., Finnema, S. J., et al. (2018) · Journal of Nuclear Medicine · Cited by 10 · see citing works

Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans

Lubberink, M., Appel, L., Gaging, J., Lindskog, K., Danfors, T., Larsson, E., Kumlien, E., & Antoni, G. (2017) · Journal of Nuclear Medicine · Cited by 9 · see citing works

Medicinal Chemistry strategies for PET tracer discovery

Andrés, J. I., & Schmidt, M. E. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.10.002 · Cited by 8 · see citing works

F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET

Holmes, S. E., Finnema, S. J., Davis, M., DellaGioia, N., Naganawa, M., Nabulsi, N., Matuskey, D., Pietrzak, R. H., Duman, R. S., Sanacora, G., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.02.763 · Cited by 5 · see citing works

Neuroreceptor Mapping

(2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_3427 · Cited by 2 · see citing works

[P2–395]: DECREASED SYNAPTIC DENSITY IN EARLY ALZHEIMER's DISEASE ASSESSED WITH [18F]UCB‐H‐PET

Salmon, É., Bahri, M. A., Manard, M., Plenevaux, A., Becker, G., Seret, A., Mella, C., Aerts, J. J., Giacomelli, F., Luxen, A., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.1050 · Cited by 1 · see citing works

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020835 · Cited by 200 · see citing works

The use of neuroimaging techniques in the early and differential diagnosis of dementia

Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 186 · see citing works

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S. G., Suárez‐Calvet, M., Karikari, T. K., Schöll, M., Joie, R. L., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 182 · see citing works

Fluid Biomarkers for Synaptic Dysfunction and Loss

Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works

The role of neuroimaging in Parkinson’s disease

Bidesi, N., Andersen, I. V., Windhorst, A. D., Shalgunov, V., & Herth, M. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15516 · Cited by 147 · see citing works

Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach

Smailović, U., & Jelić, V. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00169-0 · Cited by 143 · see citing works

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102 · see citing works

In vivo tau pathology is associated with synaptic loss and altered synaptic function

Coomans, E. M., Schoonhoven, D. N., Tuncel, H., Verfaillie, S. C. J., Wolters, E. E., Boellaard, R., Ossenkoppele, R., den Braber, A., Scheper, W., Schober, P. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00772-0 · Cited by 101 · see citing works

Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease

Delva, A., Weehaeghe, D. V., Koole, M. J. B., Laere, K. V., & Vandenberghe, W. (2020) · Movement Disorders · doi:10.1002/mds.28216 · Cited by 97 · see citing works

Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease

Leuzy, A., Cullen, N. C., Mattsson, N., & Hansson, O. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000904 · Cited by 87 · see citing works

Imaging Synaptic Density: The Next Holy Grail of Neuroscience?

Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67 · see citing works

Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review

Asken, B. M., & Rabinovici, G. D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01197-4 · Cited by 68 · see citing works

Detecting Early Cognitive Decline in Alzheimer’s Disease with Brain Synaptic Structural and Functional Evaluation

Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66 · see citing works

Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study

Michiels, L., Delva, A., van Aalst, J., Ceccarini, J., Vandenberghe, W., Vandenbulcke, M., Koole, M., Lemmens, R., & Laere, K. V. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117877 · Cited by 59 · see citing works

Carbon-11: Radiochemistry and Target-Based PET Molecular Imaging Applications in Oncology, Cardiology, and Neurology

Nerella, S. G., Bhattacharya, A., Joshi, R. K., Nagaraj, C., Bharath, R. D., & Kumar, P. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01053 · Cited by 55 · see citing works

Synthesis and Preclinical Evaluation of an 18 F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [ 18 F]SynVesT-2

Cai, Z., Li, S., Zhang, W., Pracitto, R., Wu, X., Baum, E. J., Finnema, S. J., Holden, D., Toyonaga, T., Lin, S.-F., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00618 · Cited by 54 · see citing works

Synaptic Loss in Frontotemporal Dementia Revealed by [ <scp> ¹¹ C </scp> ] <scp>UCB‐J Positron Emission Tomography</scp>

Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53 · see citing works

Synaptic density in carriers of C9orf72 mutations: a [¹¹C]UCB‐J PET study

Malpetti, M., Holland, N., Jones, P. S., Ye, R., Cope, T. E., Fryer, T. D., Hong, Y. T., Savulich, G., Rittman, T., Passamonti, L., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51407 · Cited by 44 · see citing works

Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals

Öhrfelt, A., Benedet, A. L., Ashton, N. J., Kvartsberg, H., Vandijck, M. L. J., Weiner, M. W., Trojanowski, J. Q., Shaw, L. M. J., Zetterberg, H., Blennow, K., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201417 · Cited by 44 · see citing works

Binding of the synaptic vesicle radiotracer [ ¹¹ C]UCB-J is unchanged during functional brain activation using a visual stimulation task

Smart, K., Liu, H., Matuskey, D., Chen, M.-K., Torres, K., Nabulsi, N., Labaree, D., Ropchan, J., Hillmer, A. T., Huang, Y., et al. (2021) · Journal of Cerebral Blood Flow &amp; Metabolism · doi:10.1177/0271678x20946198 · Cited by 42 · see citing works

Tracing synaptic loss in Alzheimer's brain with SV2A PET‐tracer UCB‐J

Kumar, A., Scarpa, M., & Nordberg, A. K. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13720 · Cited by 35 · see citing works

A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16

Zheng, C., Holden, D., Zheng, M., Pracitto, R., Wilcox, K. C., Lindemann, M., Felchner, Z., Zhang, L., Tong, J., Fowles, K., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05597-5 · Cited by 34 · see citing works

Inhibiting Epileptiform Activity in Cognitive Disorders: Possibilities for a Novel Therapeutic Approach

Horvath, A. A., Csernus, E. A., Lality, S., Kaminski, R. M., & Kamondi, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.557416 · Cited by 33 · see citing works

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Cybulska, K. A., Perk, L. R., Booij, J., Laverman, P., & Rijpkema, M. (2020) · Molecules · doi:10.3390/molecules25030482 · Cited by 30 · see citing works

Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment

Wang, J., Huang, Q., He, K., Li, J., Guo, T., Yang, Y., Lin, Z., Li, S., Vanderlinden, G., Huang, Y. H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13817 · Cited by 27 · see citing works

Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non‐human primate and human brain

Varnäs, K., Stepanov, V., & Halldin, C. (2020) · Synapse · doi:10.1002/syn.22157 · Cited by 25 · see citing works

Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET

Andersen, K. B., Hansen, A. K., Knudsen, K., Schacht, A. C., Damholdt, M. F., Brooks, D. J., & Borghammer, P. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.007 · Cited by 25 · see citing works

Synaptic vesicle glycoprotein 2A (SV2A) levels in the cerebral cortex in patients with Alzheimer's disease: a radioligand binding study in postmortem brains

Mikkelsen, J. D., Kaad, S., Aripaka, S. S., & Finsen, B. R. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.05.003 · Cited by 25 · see citing works

The role of microRNA-485 in neurodegenerative diseases

Ryu, I. S., Kim, D. H., Cho, H., & Ryu, J. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 24 · see citing works

Proteomic identification of select protein variants of the SNARE interactome associated with cognitive reserve in a large community sample

Ramos‐Miguel, A., Jones, A. A., Petyuk, V., Barakauskas, V., Barr, A. M., Leurgans, S. E., Jager, P. L. D., Casaletto, K. B., Schneider, J. A., Bennett, D. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02282-7 · Cited by 20 · see citing works

The associations between synaptic density and “A/T/N” biomarkers in Alzheimer’s disease: An 18 F-SynVesT-1 PET/MR study

Li, J., Huang, Q., Qi, N., He, K., Li, S., Huang, L., Pan, F., Ren, S., Hua, F., Huang, Y. H., et al. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241230733 · Cited by 20 · see citing works

Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour

Glorie, D., Verhaeghe, J. A. J., Miranda, A., Lombaerde, S. D., Stroobants, S. G., & Staelens, S. G. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00721-2 · Cited by 19 · see citing works

Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress

Erkizia-Santamaría, I., Horrillo, I., Martínez-Álvarez, N., Pérez-Martínez, D., Rivero, G., Erdozain, A. M., Meana, J. J., & Ortega, J. E. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03421-4 · Cited by 22 · see citing works

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

Öhrfelt, A., Dumurgier, J., Zetterberg, H., Vrillon, A., Ashton, N. J., Kvartsberg, H., Bouaziz-Amar, É., Hugon, J., Paquet, C., & Blennow, K. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00748-6 · Cited by 19 · see citing works

Current status of PET tracers for the early diagnosis of Alzheimer's disease

Li, Y.-Y., Liu, T., Zeng, Q., & Cui, M.-C. (2024) · Trends in Analytical Chemistry (TrAC) · doi:10.1016/j.trac.2024.117546 · Cited by 14 · see citing works

Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications

Ni, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18 · see citing works

Preliminary Assessment of Reference Region Quantification and Reduced Scanning Times for [ 18 F]SynVesT-1 PET in Parkinson’s Disease

Smart, K. A., Uribe, C., Desmond, K. L., Martin, S. L., Vasdev, N., & Strafella, A. P. (2023) · Molecular Imaging · doi:10.1155/2023/1855985 · Cited by 17 · see citing works

Etiology and Clinical Significance of Network Hyperexcitability in Alzheimer’s Disease: Unanswered Questions and Next Steps

Samudra, N. P., Ranasinghe, K. G., Kirsch, H. E., Rankin, K. P., & Miller, B. L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220983 · Cited by 17 · see citing works

Synaptic density in aging mice measured by [18F]SynVesT-1 PET

Xiong, M., Roshanbin, S., Sehlin, D., Hansen, H. D., Knudsen, G. M., Rokka, J., Eriksson, J., & Syvänen, S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120230 · Cited by 12 · see citing works

Improved synthesis of SV2A targeting radiotracer [11C]UCB-J

Rokka, J., Schlein, E., & Eriksson, J. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0080-5 · Cited by 12 · see citing works

SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement

Botermans, W., Koole, M. J. B., Laere, K. V., Savidge, J. R., Kemp, J. A., Sunaert, S. G., Duffy, M. M., Ramael, S., Cesura, A. M., D’Ostilio, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066447 · Cited by 13 · see citing works

Low dose of levetiracetam counteracts amyloid β-induced alterations of hippocampal gamma oscillations by restoring fast-spiking interneuron activity

Isla, A. G., Balleza‐Tapia, H., Chu, F., Chen, G., Johansson, J., Nilsson, P., & Fisahn, A. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114545 · Cited by 12 · see citing works

Evaluating the In Vivo Specificity of [18F]UCB-H for the SV2A Protein, Compared with SV2B and SV2C in Rats Using microPET

Navacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 12 · see citing works

Biological mechanisms of resilience to tau pathology in Alzheimer’s disease

Svenningsson, A. L., Bocancea, D. I., Stomrud, E., van Loenhoud, A. C., Barkhof, F., Mattsson, N., Palmqvist, S., Hansson, O., & Ossenkoppele, R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01591-9 · Cited by 11 · see citing works

Time-Frequency Domain Analysis of Quantitative Electroencephalography as a Biomarker for Dementia

Simfukwe, C., An, S. S. A., & Youn, Y. C. (2025) · Diagnostics · doi:10.3390/diagnostics15121509 · Cited by 12 · see citing works

Neuroproteomics Chip-Based Mass Spectrometry and Other Techniques for Alzheimer’s Disease Biomarkers – Update

Pomilio, A. B., Vitale, A. A., & Lazarowski, A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220413094918 · Cited by 8 · see citing works

Good manufacturing procedure production of [ 18 F]SynVesT‐1 , a radioligand for in vivo positron emission tomography imaging of synaptic vesicle glycoprotein 2A

Dahl, K., Larsson, S., Bonn, P., Wallin, A., Itsenko, O., & Schöll, M. (2022) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4002 · Cited by 8 · see citing works

Spirocyclic Iodonium Ylides for Fluorine‐18 Radiolabeling of Non‐Activated Arenes: From Concept to Clinical Research

Chassé, M., Pees, A., Lindberg, A., Liang, S. H., & Vasdev, N. (2023) · The Chemical Record · doi:10.1002/tcr.202300072 · Cited by 8 · see citing works

[18F]SynVest-1 PET imaging in people with Parkinson’s disease

Martin, S. L., Uribe, C., Desmond, K. L., Narciso, L., Dolman, B., Torres‐Carmona, E., Boileau, I., Graff‐Guerrero, A., Vasdev, N., & Strafella, A. P. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf258 · Cited by 7 · see citing works

A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders

Husain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M. S., Ahmed, F., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05788-y · Cited by 8 · see citing works

Associations between fluid biomarkers and PET imaging ([11C]UCB‐J) of synaptic pathology in Alzheimer's disease

Nilsson, J., Mecca, A. P., Ashton, N. J., Salardini, E., O’Dell, R. S., Carson, R. E., Benedet, A. L., Blennow, K., Zetterberg, H., van Dyck, C. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70403 · Cited by 6 · see citing works

Preclinical PET imaging in epileptogenesis: towards identification of biomarkers and therapeutic targets

Hernández‐Martín, N., Pozo-Cabanell, I., de la Rosa, R. F., García‐García, L., Gómez-Oliver, F., Pozo, M. A., Brackhan, M., & Bascuñana, P. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01237-3 · Cited by 5 · see citing works

Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain

Mikkelsen, J. D., Aripaka, S. S., Bascuñana, P., Bankstahl, M., Bankstahl, J. P., & Pazarlar, B. A. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.07.020 · Cited by 5 · see citing works

Molecular Positron Emission Tomography and Single-Photon Emission Computed Tomography Imaging for Understanding the Neurobiological Mechanisms of Electroconvulsive Therapy

Laroy, M., Laere, K. V., Vandenbulcke, M., Emsell, L., & Bouckaert, F. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001094 · Cited by 4 · see citing works

Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study

Pazarlar, B. A., Madsen, C. A., Oyar, E. Ö., Eğilmez, C. B., & Mikkelsen, J. D. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.106926 · Cited by 4 · see citing works

A comparative study on Suzuki‐type 11 C‐methylation of aromatic organoboranes performed in two reaction media

Rokka, J., Nordeman, P., Roslin, S., & Eriksson, J. (2021) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3932 · Cited by 3 · see citing works

Pharmacodynamic interactions between seletracetam and antiseizure comedications in the human photosensitivity model

Löscher, W., Stockis, A., Klein, P., & Trenité, D. G. A. K.-N. (2025) · Epilepsia · doi:10.1111/epi.18420 · Cited by 2 · see citing works

Disease signatures: Biomarkers/indicators of neurodegeneration

Zetterberg, H., & Bähr, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.05.004 · Cited by 2 · see citing works

Quantitative monitoring of ketamine’s impact on synaptic density using 11C-UCB-J PET imaging in the corticosterone mouse model of anxiety/depression

Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1 · see citing works

Potential of [11C]UCB-J as a PET tracer for islets of Langerhans

Puuvuori, E., Rokka, J., Carlsson, P., Li, Z., Eriksson, J., & Eriksson, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-04188-6 · Cited by 1 · see citing works

Exploring synaptic density patterns in cerebral small vessel disease: insights from [18F]SynVesT-1 PET imaging

Xiao, L., Zhao, T., Yang, Y., Zhong, J., Liao, D., Zhang, B., Li, J., Tu, R., Hou, J., Wang, X., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07808-3 · Cited by 1 · see citing works

Integrative Structural Bioinformatics and Molecular Dynamics Analyses of Synaptic Vesicle Proteins and Their Water-Soluble QTY-Variants Reveal Membrane Constraints and Evolutionary Coupling of T ⇔ V

Karagöl, T., Karagöl, A., & Zhang, S. (2026) · Journal of Molecular Evolution · doi:10.1007/s00239-026-10315-6 · Cited by 1 · see citing works

Evaluation of [11C]UCB-A positron emission tomography in human brains

Xiong, M., Lubberink, M., Appel, L., Fang, X. T., Danfors, T., Kumlien, E., & Antoni, G. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01117-2 · Cited by 1 · see citing works

Identification de biomarqueurs sanguins chez des sujets à risque pour la maladie d’Alzheimer

Potier, M. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.02.003 · Cited by 1 · see citing works

Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development

Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6

Blocking the FAM19A5-LRRC4B complex enhances neurite growth and synapse assembly.Preprint

Seong, J. Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2589038/v1

Single-dose rapamycin increases brain glucose metabolism but reduces synaptic density in Long- Evans ratsPreprint

Gudmundsen, F., Li, Z., Baun, C., Svensson, J. E., Langkjær, N., Palner, M., & Plavén‐Sigray, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.11.642549

Multimodal Imaging Investigations of Human Brain Function and Plasticity

Moore, M., Katsumi, Y., Iordan, A. D., Dolcos, S. M., & Dolcos, F. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197677131.013.32

Additional file 1 of Evaluation of [11C]UCB-A positron emission tomography in human brains

Xiong, M., Lubberink, M., Appel, L., Fang, X. T., Danfors, T., Kumlien, E., & Antoni, G. (2024) · Figshare · doi:10.6084/m9.figshare.26735010

Additional file 2 of A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders

Husain, M. O., Jones, B. D. M., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M., Ahmed, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26066220

Additional file 1 of In vivo tau pathology is associated with synaptic loss and altered synaptic function

Coomans, E. M., Schoonhoven, D. N., Tuncel, H., Verfaillie, S. C. J., Wolters, E. E., Boellaard, R., Ossenkoppele, R., den Braber, A., Scheper, W., Schober, P. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13725141

Additional file 1 of Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review

Asken, B. M., & Rabinovici, G. D. (2021) · Figshare · doi:10.6084/m9.figshare.14651208

Additional file 3 of A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders

Husain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M., Ahmed, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26736453

Additional file 1 of A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders

Husain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M., Ahmed, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26066140

Additional file 1 of Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour

Glorie, D., Verhaeghe, J., Miranda, A., Lombaerde, S. D., Stroobants, S. G., & Staelens, S. G. (2020) · Figshare · doi:10.6084/m9.figshare.13237747

Autoradiographic assessment of SynVesT-1 revealed changes in non-displaceable binding with demyelination and remyelination: implications for SV2A PET analysis

Panichnantakul, P., Shaw, R., Burianova, V. K., McErlain, H., Sutherland, A., Williams, A., Waldman, A. D., & Tavares, A. A. S. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01391-2

Sleep differentially modulates synaptic vesicle protein 2A and spine density across cortical regions and development

Ma, J., Braun, A., Oskamp, A., Kricsfalussy-Hrabár, L., Hermes, N., Djakkani, S., Holz, U., Jakobs, S., Klein, S., Stüsgen, S., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116676

First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy

Qiao, Z., Li, S., Zhang, Y., Zhao, X., Yang, Z., Sun, X., Chen, H., Cheng, X., Liu, Y., Ai, L., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c01052

SV2A PET imaging in human neurodegenerative diseases

Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 33 · see citing works

Synaptic PET Imaging in Neurodegeneration

Chen, M., Matuskey, D., Finnema, S. J., & Carson, R. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_10

Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications

Mercier, J., Provins, L., & Valade, A. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.11.003 · Cited by 55 · see citing works

Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A: Biomarkers of synaptic density in Alzheimer's disease

Mecca, A. P., Ashton, N. J., Chen, M., O’Dell, R. S., Toyonaga, T., Zhao, W., Young, J. J., Salardini, E., Bates, K. A., Ra, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70344 · Cited by 10 · see citing works

Imaging of Synaptic Density in Neurodegenerative Disorders

Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104 · see citing works